FDA sets April 2027 decision date for lead drug
- Immunome has no product sales yet and relies on investor funding to advance its pipeline.
- The FDA accepted the application for its lead drug, varegacestat, setting a decision date of April 28, 2027.
- The Phase 3 RINGSIDE trial cut the risk of disease progression or death by 84% versus placebo in topline results.
- The company has advanced its early pipeline, dosing the first participants in Phase 1 trials for IM-1617 and IM-3050 in mid-2026.
- The biggest open question is whether varegacestat can win approval and compete with OGSIVEO, an approved drug.
A cleaner lead story, still not a business
Immunome is making real progress. In July 2026, the FDA accepted the approval application for varegacestat, setting a target action date of April 28, 2027. It also dosed the first patients in Phase 1 trials for IM-1617 and IM-3050. That is strong execution for a company whose value depends almost fully on future drugs.
The bull case is now easier to state. Varegacestat has positive Phase 3 topline data in desmoid tumors, including an 84% reduction in the risk of disease progression or death versus placebo. With the FDA acceptance, Immunome is on a clear path toward a potential first commercial launch in early 2027.
The bear case did not go away. Immunome has not received FDA approval for any product. It also has to sell into a market where OGSIVEO is already approved for desmoid tumors. The company has accumulated a deficit of $855.1 million through June 2026 and expects losses to continue. Management says it will need more financing to support operations and commercialization if varegacestat is approved.
The next year is mostly about proof. Watch for the FDA decision on varegacestat by April 2027, initial IM-1021 lymphoma data in 2026, and IND submissions for the preclinical candidates IM-1340 and IM-1335.
No sales, funded by investors
Immunome does not make money from selling drugs today. Its collaboration with AbbVie ended in July 2025, removing its prior source of revenue. The company is now entirely dependent on equity financing and potential future partnerships.
The company spends cash to move drug candidates through lab work, human trials, FDA filings, and launch preparation. The model is highly capital-intensive, focused on building a broad pipeline through internal discovery and external asset acquisitions.
Funding comes mainly from stock sales. Immunome reported an accumulated deficit of $855.1 million at June 30, 2026, and while management expects current cash to fund operations for at least 12 months, a full launch and several clinical trials will likely require more capital.
The model works only if at least one drug becomes valuable enough to pay for years of losses. Until then, shareholders carry dilution risk, meaning future stock sales could reduce each current share's claim on the company.
One late drug, several early shots
Varegacestat
Varegacestat is an oral gamma secretase inhibitor. The FDA accepted its New Drug Application in July 2026 with a target action date of April 28, 2027.
IM-1021
IM-1021 is a ROR1 antibody-drug conjugate in Phase 1 testing. Initial data for B-cell lymphoma patients is planned for presentation in 2026.
IM-3050
IM-3050 is a FAP-targeted radioligand therapy. The first participant was dosed in a Phase 1 trial in July 2026.
IM-1617
IM-1617 is an antibody-drug conjugate aimed at an undisclosed receptor. The first participant was dosed in a Phase 1 clinical trial in June 2026.
IM-1340
IM-1340 is a preclinical solid tumor antibody-drug conjugate. Immunome plans to submit an IND in mid-2026.
IM-1335
IM-1335 is another preclinical solid tumor antibody-drug conjugate. Immunome expects to submit an IND in late 2026.
One segment, spending tells the story
Immunome reports one operating segment and generates no product revenue. The chart uses Q1 2026 research and development expense allocation by program, with indirect R&D shown separately.
What could break the case
FDA delays or denies approval
High impact · Medium oddsVaregacestat is the main near-term value driver. The FDA accepted the application in July 2026, but approval is not guaranteed. A request for more data or a narrower label would hurt the launch case.
OGSIVEO blocks the launch
High impact · Medium oddsVaregacestat would not enter an empty market. OGSIVEO is already approved for desmoid tumors. Immunome needs the full RINGSIDE data and safety profile to show why its drug should be used.
Cash burn forces dilution
Medium impact · High oddsImmunome had an $855.1 million accumulated deficit at June 30, 2026. A full launch and several trials will require substantial capital, which could mean more stock sales or debt.
Early pipeline data disappoints
Medium impact · Medium oddsIM-1021, IM-3050, and IM-1617 are in Phase 1 trials. Many cancer drugs fail between Phase 1 and approval. Weak safety or low response rates would reduce the value of the broader platform.
Third parties slow the work
Medium impact · Medium oddsImmunome relies on outside groups for manufacturing and supply. Supply chain constraints involving diagnostic radiotracers have previously delayed the IM-3050 trial.
In one breath
Does Immunome have revenue?
Not from product sales. Its AbbVie collaboration ended in July 2025, and the company currently generates no revenue.
What is Immunome's most important drug?
Varegacestat is the lead asset. It has positive Phase 3 topline results in desmoid tumors and an FDA target action date of April 28, 2027.
What is an ADC?
An antibody-drug conjugate is a targeted cancer drug. It uses an antibody to find cells with a certain marker, then delivers a toxic payload meant to kill those cells.
What should investors watch next?
The biggest item is the FDA decision on varegacestat by April 2027. Investors should also watch for early clinical data from IM-1021 in 2026.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Immunome, Inc. in Finn's Biotechnology industry ranking.
